The Impact of Surgical Treatment of Endometriomas on Ovarian Reserve

Saad Amer20 enrolled

Overview

The aim of this study is to assess which of two commonly used surgical procedures in the treatment of ovarian cysts called endometriomas (cutting out of the cyst - "cystectomy", or draining it and cauterising it's inner lining - "ablation") causes the least damage to the ovary and is therefore best at maintaining the future fertility potential of a patient.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Endometriosis

Interventions

Surgery for ovarian endometriomaPROCEDURE

Patients undergoing surgery for ovarian endometrioma

Surgery for ovarian endometriomaPROCEDURE

Patients undergoing surgery for ovarian endometrioma

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 42 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women undergoing laparoscopic surgery for treatment of unilateral endometriomas measuring ≥ 3cm and ≤ 8cm in diameter Exclusion Criteria: * Patients who have received oestrogen suppressing drugs (e.g. oral contraceptive pills, GnRHa) during the previous six months * Patients who have previously undergone surgical treatment of endometriomas * Patients with bilateral endometriomas * Patients with endometriomas of less than 3cm in size or more than 8cm in size * Pre-surgical evidence of reduced ovarian reserve * Pregnant patients * Patients unable to give informed consent e.g. patients with mental incapacity

Locations (1)

Royal Derby Hospital

Derby, United Kingdom

RECRUITING

Outcomes

Primary Outcomes

Anti-Mullerian Hormone (AMH)

Change in anti-mullerian hormone level after surgery (at one week, three months and six months)

Time frame: 6 months post-operatively

Secondary Outcomes

Follicle Stimulating Hormone (FSH)

Change in follicle stimulating hormone levels after surgery (at one week, three months and six months)

Time frame: 6 months

Antral Follicle Count (AFC)

Change in AFC after surgery (at three months)

Time frame: 3 months

Central Contacts

Saad Amer, MD, MRCOG

CONTACT

+44(1332)724612 saad@amer@nottigham.ac.uk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.